Using Blood-Free Insulin, Transferrin, and Albumin Supplements to Reduce and Eliminate FBS in Research & Manufacturing

Stream the Full Webinar Recording Now! 

See How Blood-Free Supplements Add Consistency & Reduce Variability

It is well known that serum and other animal-derived components can create inconsistency in cell culture, leading to variability in cell growth, phenotype, and functional performance. Therefore, it is critical to both manufacturing and research applications to reduce or completely eliminate the use of these ingredients.

InVitria offers blood-free cell culture supplements that effectively reduce the amount of serum needed in routine cell culture by replacing the insulin, transferrin, and albumin found in serum with recombinant versions. These supplements, known as ITSE AF, ITS AF, and ITSE + A AF, also serve as a suitable foundation for fully serum and blood-free cell expansion.

Learn the Benefits of Blood-Free Supplements

During this webinar we demonstrated the utility of these supplements as serum reducers in research cell lines as well as in blood-free complete media formulations in stem cell systems.

Stream this webinar recording and you will:

  • Understand ideal applications for reduced serum cell culture    
  • Learn how to effectively reduce serum using ITSE, ITS, and ITSE + A
  • See how to build serum-free formulations around ITSE, ITS, and ITSE + A

Fill in the form to view the recording of this webinar now!

Stream the Full Webinar Recording:


“InVitria’s ITSE Animal-Free works well, and better than our alternative product from another supplier.”

Senior Cell Culture Scientist,

Ludwig Institute for Cancer Research



Randy AlfanoPresented by:

Dr. Randall Alfano, Ph.D. 
Vice President, InVitria Product Development
Dr. Alfano joined InVitria in 2012 and currently leads the product development team, where he utilizes his expertise in media design and optimization for biomanufacturing and stem/primary cells. Prior to joining the company, Dr. Alfano was the Process Development Manager for XBiotech in Austin, TX where he specialized in the development and optimization of the company’s cell culture processes in mammalian cells for cancer biologics. Previously, he was promoted from Postdoctoral Fellow to Senior Scientist at the Cancer Research Institute of Scott and White Hospital where he developed in vivo animal models for metastatic prostate cancer and was instrumental in developing thorough in vitro and in vivo models for immunostimulatory antigens. Dr. Alfano received his Ph.D. from Texas A&M Health Science Center College of Medicine.